GlassScriptPhysician profile
Lolie C Yu
NPI 1063433084
$3,282.05
in general payments reported to CMS, 2019-2025
33 companies · $66.43 in 2025
The $66.43 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $294 · 2021: $279 · 2022: $352 · 2023: $541 · 2024: $241 · 2025: $66.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.56 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $752.61 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $404.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $322.22 | 2019-2024 | |
| Csl Behring | $195.20 | 2019-2023 | Idelvion, Hemgenix |
| Novo Nordisk INC | $193.97 | 2019-2025 | |
| Sobi, INC | $187.13 | 2019-2023 | |
| Btg International INC. | $140.17 | 2020-2024 | |
| Seagen INC. | $139.80 | 2023 | Adcetris |
| Bioverativ Therapeutics INC. | $110.26 | 2019 | |
| Octapharma USA, INC. | $103.55 | 2022-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
| Emd Serono, INC. | $100.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $96.97 | 2019-2023 | Ultomiris, Koselugo |
| Pfizer INC. | $96.93 | 2023-2024 | |
| Genentech USA, INC. | $68.61 | 2019-2024 | Hemlibra |
| Emmaus Medical, INC. | $55.28 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $50.83 | 2020-2021 | |
| Hema Biologics, LLC | $50.32 | 2023 | Sevenfact |
| Fennec Pharmaceuticals, INC. | $27.91 | 2023 | Pedmark |
| Genetix Biotherapeutics INC | $21.48 | 2023 | |
| Epizyme, INC. | $21.31 | 2021 | |
| Chiesi USA, INC. | $19.48 | 2020 | |
| Rare Disease Therapeutics, INC. | $18.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.22 | 2020 | |
| Medexus Pharma, INC. | $15.00 | 2021 | |
| Uswm, LLC | $14.97 | 2025 | Iwilfin |
| Horizon Therapeutics Plc | $14.56 | 2019 | |
| Duchesnay USA Incorporated | $13.19 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $12.10 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lolie Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.